1. Home
  2. CTNM vs SCM Comparison

CTNM vs SCM Comparison

Compare CTNM & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • SCM
  • Stock Information
  • Founded
  • CTNM 2009
  • SCM 2012
  • Country
  • CTNM United States
  • SCM United States
  • Employees
  • CTNM N/A
  • SCM N/A
  • Industry
  • CTNM
  • SCM Finance/Investors Services
  • Sector
  • CTNM
  • SCM Finance
  • Exchange
  • CTNM Nasdaq
  • SCM Nasdaq
  • Market Cap
  • CTNM 453.0M
  • SCM 370.0M
  • IPO Year
  • CTNM 2024
  • SCM 2012
  • Fundamental
  • Price
  • CTNM $17.21
  • SCM $13.98
  • Analyst Decision
  • CTNM Strong Buy
  • SCM Hold
  • Analyst Count
  • CTNM 4
  • SCM 2
  • Target Price
  • CTNM $29.25
  • SCM $13.63
  • AVG Volume (30 Days)
  • CTNM 74.8K
  • SCM 161.4K
  • Earning Date
  • CTNM 11-06-2024
  • SCM 11-07-2024
  • Dividend Yield
  • CTNM N/A
  • SCM 11.44%
  • EPS Growth
  • CTNM N/A
  • SCM 307.51
  • EPS
  • CTNM N/A
  • SCM 1.96
  • Revenue
  • CTNM N/A
  • SCM $107,143,385.00
  • Revenue This Year
  • CTNM N/A
  • SCM $2.75
  • Revenue Next Year
  • CTNM N/A
  • SCM $1.08
  • P/E Ratio
  • CTNM N/A
  • SCM $7.14
  • Revenue Growth
  • CTNM N/A
  • SCM 5.88
  • 52 Week Low
  • CTNM $13.27
  • SCM $12.48
  • 52 Week High
  • CTNM $22.00
  • SCM $14.68
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • SCM 53.18
  • Support Level
  • CTNM N/A
  • SCM $13.65
  • Resistance Level
  • CTNM N/A
  • SCM $14.14
  • Average True Range (ATR)
  • CTNM 0.00
  • SCM 0.22
  • MACD
  • CTNM 0.00
  • SCM -0.02
  • Stochastic Oscillator
  • CTNM 0.00
  • SCM 63.22

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: